ENZ (Enzo Biochem) COGS-to-Revenue : 0.63 (As of Oct. 2024)

View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem COGS-to-Revenue?

Enzo Biochem's Cost of Goods Sold for the three months ended in Oct. 2024 was $3.93 Mil. Its Revenue for the three months ended in Oct. 2024 was $6.21 Mil.

Enzo Biochem's COGS to Revenue for the three months ended in Oct. 2024 was 0.63.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Enzo Biochem's Gross Margin % for the three months ended in Oct. 2024 was 36.70%.

Enzo Biochem COGS-to-Revenue Historical Data

The historical data trend for Enzo Biochem's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem COGS-to-Revenue Chart

Enzo Biochem Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

COGS-to-Revenue

Get a 7-Day Free Trial

0.69

0.54

0.59

0.63

0.54

Enzo Biochem Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
COGS-to-Revenue	Get a 7-Day Free Trial															0.56	0.51	0.53	0.57	0.63

Enzo Biochem COGS-to-Revenue Calculation

Enzo Biochem's COGS to Revenue for the fiscal year that ended in Jul. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	17.275	/	31.907
	=	0.54

Enzo Biochem's COGS to Revenue for the quarter that ended in Oct. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	3.933	/	6.213
	=	0.63

Enzo Biochem (NYSE:ENZ) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Enzo Biochem's Gross Margin % for the three months ended in Oct. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	3.933 / 6.213
	=	36.70 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Enzo Biochem COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

0IHV:UK

Address

21 Executive Boulevard, Farmingdale, NY, USA, 11735

Website

https://www.enzo.com

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.

Executives

Steven J Pully	director	9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf	10 percent owner	105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian	officer: Chief Executive Officer	527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert	officer: Interim CFO	C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon	officer: Chief Operating Officer	527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff	director	2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench	officer: CHIEF FINANCIAL OFFICER	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp	10 percent owner	HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri	director	455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv	10 percent owner	2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer	director	ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank	10 percent owner, other: See Remarks	ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc	10 percent owner	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203